The World Health Organization (WHO) is rolling out several plans to jumpstart biosimilar competition to make biologic cancer treatments more accessible in low- and middle-income countries. At the top of the agenda is a pilot project to prequalify biosimilars referencing biologics on the WHO Essential Medicines List.